Cempra (NASDAQ:CEMP) has been under a strong bear grip, hence the stock is down -5.48% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.88% in the past 1 week. The stock has risen by 5.21% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.95% in the past 4 weeks.
The company shares have dropped -50.25% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $46.99 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $17.97 and the 200 Day Moving Average price is recorded at $18.51.
The stock has recorded a 20-day Moving Average of 0.95% and the 50-Day Moving Average is 3.97%.
Cempra (NASDAQ:CEMP): stock turned positive on Friday. Though the stock opened at $17.81, the bulls momentum made the stock top out at $18.09 level for the day. The stock recorded a low of $17.6501 and closed the trading day at $17.98, in the green by 0.95%. The total traded volume for the day was 677,958. The stock had closed at $17.81 in the previous days trading.
In an insider trading activity, Moore David, officer (Chief Commercial Officer) of Cempra, Inc., had purchased 500 shares on March 1, 2016. The total value of the transaction was $8,090. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.